Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Korea
Biotech
Tolerance inks $260M deal for thymus-targeting fusion protein
Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein.
Nick Paul Taylor
Aug 19, 2026 10:00am
Neok exits stealth with $75M to take bispecific ADCs into clinic
Nov 4, 2025 7:00am
GemVax's peptide drug fails phase 2a neurodegenerative trial
Oct 29, 2024 11:28am
Readying for next pandemic, Korea's SK pumps $261M into R&D site
Feb 8, 2023 9:40am
Boston Scientific offers $230M for Korean stent maker
Jun 15, 2022 12:15pm
Bioasis, Neuramedy sign blood-brain barrier pact for $72M
May 11, 2022 10:55am
